Sandini M, et al. - In this retrospective cohort study conducted at four academic medical centers, researchers ascertained if neoadjuvant treatment (NT) affects muscle mass and adipose tissue in patients with borderline resectable pancreatic cancer and locally advanced pancreatic cancer, and determined whether there were potential differences between patients who ultimately had resection vs those who did not. They found that patients with pancreatic cancer did not experience muscle wasting; however, they did note a significant loss of adipose tissue during neoadjuvant chemotherapy. Findings revealed that an increase in muscle tissue during NT was related to resectability.